Sign In   |   Register
News: Publications

New Commentary article: ESC/EAS Task Force provides practical guidance for PCSK9 inhibitors

05 December 2016   (0 Comments)
Share |

ESC/EAS Task Force provides practical guidance for PCSK9 inhibitors; who to target, LDL-thresholds, future insights is the title of a new Commentary article from Scientific Editor Jane Stock.

"The availability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, for use in the clinic has highlighted the need for practical guidance. In response, this Joint Task Force of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) has provided a document to aid clinicians in the appropriate use of these novel treatments. In balancing the clinical need for these treatments with their cost, the Task Force has not surprisingly taken a conservative approach, especially given the lack of clinical outcomes evidence to date..."

Read the full Commentary


Membership Software Powered by YourMembership  ::  Legal